Forget Ukraine crisis: Here are 12 stocks to buy in March for high returns

[caption id= 'attachment_1050191' align='aligncenter' width='1024'] As Indian market seems to be spooked by the crisis in far away Ukraine, it is time to do some shopping. US president has warned that US will mull economic and diplomatic sanctions that will isolate Russia if it doesn't stop its military threat to Crimea. Brent Crude spiked 2 percent as the Ukraine crisis raised concerns about a disruption of Russian natural gas supplies. Nymex too rose to USD 104 dollars. Precious metal gold is holding on to its near 4-month highs. Here are top 12 stocks that Edelweiss recommends to buy in March. "These are high conviction stock ideas that have the potential to generate market-beating returns over the next 12-18 months," it said in a note. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Alembic Pharma It is a leader in several sub-segments of the Anti-Infective Therapeutic segment. Increased its revenues from chronic segment from 45% to over 50%. Negligible debt on books, company plans to become ZERO debt by FY15E. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Bajaj Finance Has exhibited strong growth momentum with 75% CAGR growth in AUM over the last three years. BFL is maintaining the balance with the profitability (consumer segment) and scalability (infrastructure segment). [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] ICICI Bank Guidance of 20% domestic advance growth, NIMs of 3.2% for FY14, cost/income to be capped at 40%, CASA at 38- 40% and credit cost of 75bps will sustain the RoA/RoE at similar levels. Average CASA is 38-40% which keeps cost of funds low and add to net interest margin. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Larsen & Toubro L&T witnessed strong order inflows of Rs 88000 crore in FY13 with 25% yoy growth and maintained strong inflows in 9MFY14 with Rs 67400 cr (up 23% yoy). The management aims to achieve 15% growth in order inflows in FY14 on a high base. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Lupin Lupin has a strong pipeline of products (120 products) for the US markets pending for approval. It is expected that the company would be able to get the approvals for the same in the next 2-3 years. Its total sales to grow at 17% CAGR between FY13-15E led by strong growth in US generics business over FY13-15E primarily exclusive product launches. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Motherson Sumi Systems Internal sourcing opportunities (Rs 5000 crore) , tapping customers within business segments (SMR –SMP) and vertical integration (SMR) gives us sustained sales and margin visibility over a longer period . [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Pidilite Industries Secular long term growth, healthy return ratios (>35% ROCE), robust operating & free cash flow generation, net cash balance sheet, healthy dividend payout and attractive valuations at 22.7x FY15E (19% discount to FMCG median). [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Infosys Infosys outperforms its peers in terms of operating metrics such as cash flow generation and margins. It has well managed its margins across cycles with EBITDA margins remaining in a narrow 31-35% band despite the sharp swings in the currency over the past few years. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Ipca Laboratories Domestic formulations account for around 32% of total sales where it has grown at 16% CAGR over last five years and is expected to continue to grow at a sustainable 16-17% over the next two years. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] United Spirits A 10% increase in realisations in the regular segment for USL would double domestic business profits for USL. Thus there exists significant operating leverage which is untapped. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Wipro EBITDA margins are set to rise, largely due to improvement in utilisation and new deal wins. We expect utilisation to improve from current 72% level to 80-81% range. Revenue growth to improve to 2-4% on a QoQ basis in FY14 versus the 0-2% in FY13, driven by improved client mining and enhanced deal flows. [/caption] [caption id= 'attachment_1050191' align='aligncenter' width='1024'] Zee Entertainment Enterprises As of H1-FY14, subscription revenues contributed around 44% to ZEE's total revenues. We expect subscription revenues to contribute around 56% to ZEE’s total revenues by FY16. ZEE’s international revenues will further add to the company’s profitability prospects [/caption]